Evaluation for Potential Drug-Drug Interaction of MT921 Using In Vitro Studies and Physiologically-Based Pharmacokinetic Models

• Main Authors: Hyo-jeong Ryu (Author), Hyun-ki Moon (Author), Junho Lee (Author), Gi-hyeok Yang (Author), Sung-yoon Yang (Author), Hwi-yeol Yun (Author), Jung-woo Chae (Author), Won-ho Kang (Author)
• Format: Book
• Published: MDPI AG, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

MT921 is a new injectable drug developed by Medytox Inc. to reduce submental fat. Cholic acid is the active pharmaceutical ingredient, a primary bile acid biosynthesized from cholesterol, endogenously produced by liver in humans and other mammals. Although individuals treated with MT921 could be adm...